Withings has introduced the Body Scan 2, a $600 smart scale that aims to transform daily weigh-ins into comprehensive health assessments, emphasizing longevity. Launched at CES 2026, this innovative device is designed to measure over 60 biomarkers related to long-term health, including risks for hypertension and early signs of glycemic dysregulation, a precursor to diabetes. The Body Scan 2 goes beyond traditional weighing methods by offering insights into physiological changes that could be addressed early, potentially improving quality of life over time. The scale's design features a pull-up exercise bar, a glass surface, and an integrated color screen that delivers real-time metrics. It utilizes advanced technology, including eight embedded electrodes and four in the handle, to gather data that syncs automatically with the Withings app via Wi-Fi or Bluetooth. This app generates a Health Trajectory score based on the user's measurements, allowing for personalized tracking over time and identifying lifestyle adjustments to mitigate health risks. Withings emphasizes data privacy, ensuring compliance with regulations like GDPR and HIPAA. Scheduled for launch in Q2 2026, the Body Scan 2 is pending FDA clearance for certain metrics and will be available through various retailers. Withings, known for its early innovations in connected health devices, positions the Body Scan 2 as a culmination of its efforts, aiming to provide a more detailed and continuous view of health that can catch warning signs well before they develop into chronic conditions. The introduction of this smart scale reflects a broader trend in health technology focusing on proactive and preventive health management.